Clinical Trials Browser

Phase 2/3 × Prostatic Neoplasms × Ipilimumab × Clear all

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

Prostatic Neoplasms